Shield Post-Approval Study Protocol
Guardant Health, Inc.
3,375 participants
Jul 14, 2025
OBSERVATIONAL
Conditions
Summary
The Shield post-approval study (PAS) is a prospective, longitudinal study supplemented with Real World Evidence (RWE) to evaluate the longitudinal performance of Shield in an average risk population at a second round of testing for individuals between the ages of 45 and 81 at average risk of CRC using colonoscopy as the reference method.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Shield Blood Test for colo-rectal cancer Screening
Locations(56)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06880055